ACT Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

ACT Capital Management’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$853K	Hold	156,250	–	–	1.18%	19
2022 Q2	$696K	Sell	156,250 -23,167	-13%	-$137K	0.97%	23
2022 Q1	$1.59M	Hold	179,417	–	–	1.69%	14
2021 Q4	$1.58M	Buy	179,417 +11,084	+7%	+$122K	1.14%	21
2021 Q3	$1.92M	Buy	168,333 +22,500	+15%	+$304K	0.99%	22
2021 Q2	$2.45M	Buy	+145,833	New	+$4.29M	1.26%	16

Other funds holding IKT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACT Capital Management's IKT Position: Q3 2022 in Review

ACT Capital Management held its Inhibikase Therapeutics (IKT) position steady in Q3 2022 at 156,250 shares worth $853K. The position accounts for 1.18% of the portfolio, ranked #19.

ACT Capital Management first reported a position in IKT in Q2 2021 and has held it in 6 quarters since. The position peaked at $2.45M in Q2 2021. 24 funds tracked by Wall St. Rank hold IKT as of Q3 2022.

ACT Capital Management held 156,250 shares of Inhibikase Therapeutics worth $853K as of Q3 2022.
ACT Capital Management left its Inhibikase Therapeutics share count unchanged in Q3 2022.
Inhibikase Therapeutics made up 1.18% of ACT Capital Management's portfolio in Q3 2022, its #19 holding.
ACT Capital Management first reported a position in Inhibikase Therapeutics in Q2 2021 and has held it in 6 quarters since.
ACT Capital Management's Inhibikase Therapeutics position peaked at $2.45M in Q2 2021.
24 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.